Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
Hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs (HS-NSAIDs) are an emerging novel class of compounds with significant anti-inflammatory properties. They consist of a traditional NSAID to which an H(2)S-releasing moiety is covalently attached. We examined the effects of four different HS-NSAIDs on the growth properties of eleven different human cancer cell lines of six different tissue origins. Human colon, breast, pancreatic, prostate, lung, and leukemia cancer cell lines were treated with HS-aspirin, -sulindac, -iburofen, -naproxen, and their traditional counterparts. HS-NSAIDs inhibited the growth of all cancer cell lines studied, with potencies of 28- to >3000-fold greater than that of their traditional counterparts. HS-aspirin (HS-ASA) was consistently the most potent. HS-NSAIDs inhibited cell proliferation, induced apoptosis, and caused G(0)/G(1) cell cycle block. Metabolism of HS-ASA by colon cells showed that the acetyl group of ASA was hydrolyzed rapidly, followed by hydrolysis of the ester bond linking the salicylate anion to the H(2)S releasing moiety, producing salicylic acid and ADT-OH from which H(2)S is released. In reconstitution studies, ASA and ADT-OH were individually less active than the intact HS-ASA towards cell growth inhibition. Additionally, the combination of these two components representing a fairly close approximation to the intact HS-ASA, was 95-fold less active than the intact HS-ASA for growth inhibition. Taken together, these results demonstrate that HS-NSAIDs have potential anti-growth activity against a wide variety of human cancer cells.
Department of Physiology and Pharmacology, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, NY 10031, United States.
Mitali
M
Chattopadhyay
Ravinder
R
Kodela
Niharika
N
Nath
Yosef M
YM
Dastagirzada
Carlos A
CA
Velázquez-Martínez
Daniel
D
Boring
Khosrow
K
Kashfi
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000493:pharmacokinetics*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D017209:Apoptosis / Q000187:drug effects; D001241:Aspirin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D006131:Growth Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics*; D006801:Humans; D006862:Hydrogen Sulfide / Q000737:chemistry / Q000378:metabolism*; D007052:Ibuprofen / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D009288:Naproxen / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D013467:Sulindac / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D013871:Thiones / Q000737:chemistry / Q000493:pharmacokinetics*
C571293:2-(6-methoxy-naphthalen-2-yl)-propionic acid 4-(5-thioxo-5H-(1,2)dithiol-3-yl)-phenyl ester; C571295:4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-(4-isobutyphenyl)propanoate; C571292:4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-acetoxybenzoate; C571294:5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid 4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl ester; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D013871:Thiones; D013467:Sulindac; D009288:Naproxen; D001241:Aspirin; D007052:Ibuprofen; D006862:Hydrogen Sulfide